Login
Rallybio Corp logo

Rallybio Corp

rallybio.com

What Do They Do?

Develops therapies for patients with severe and rare diseases, including complement-related and iron-overload disorders.

How Do They Make Money?

Partners pay for licenses, related know-how, research and development work, and participation in joint research or development committees. Payments may include upfront fees, milestone payments, and royalties tied to product sales.

FY2025 revenue by product or service revenue
SegmentShareRevenue
License
Licensed

93%
Collaboration and license revenue
Licensed

100%

Who Are Their Customers?

Drug-development partners work with Rallybio directly on discovery and development; agreements may include licenses, research services, and joint research or development committees.

Do Revenues Turn Into Profits?

No. It lost $9M in FY2025.

Operating income, FY2025
−3854% of revenue
▲ +45% (Loss) vs FY2024 (−$60.5M, −9512%)
Net income, FY2025
−1046% of revenue
▲ +84% (Loss) vs FY2024 (−$57.8M, −9084%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $212K in Q3 FY2025
Net income
▼ Turned to a loss
vs $16M in Q3 FY2025
  • Nov 12, 2026 Rallybio expects the Avenzo merger to close Closing is anticipated after trading on November 20, 2026; a $13.90-per-share cash distribution is expected to begin November 30, 2026.
  • Nov 6, 2026 Avenzo merger closing was postponed over listing conditions Some conditions for listing the company’s shares after closing had not been met, and the cash distribution timing could be delayed.
  • May 31, 2026 Rallybio agreed to acquire Avenzo in a merger Avenzo is a clinical-stage company developing oncology therapies; the combined company is expected to operate as Avenzo Therapeutics.
  • May 3, 2026 Candid terminated its merger agreement with Rallybio Rallybio is entitled to a $50,000,000 termination fee after Candid entered an agreement with UCB.

Portfolio exits The earlier report included maternal-fetal and metabolic disease programs; the latest report says Rallybio discontinued its maternal-fetal program and sold its interest in a metabolic-disease program, while continuing work on complement and hematology programs.

Proposed strategic combination The earlier report described a rare-disease drug pipeline; the latest report proposes a merger with Candid, which is advancing T-cell engager therapies for autoimmune diseases, while Rallybio plans to reduce administrative operations.

Revenue over time
License Collaboration and license revenue
$1M$500K$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support